| Code | CSB-RA005346MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to OCX-253, targeting CHI3L1 (Chitinase-3-like protein 1), also known as YKL-40. CHI3L1 is a secreted glycoprotein that lacks enzymatic activity but plays significant roles in inflammation, tissue remodeling, and cellular responses to environmental stress. This protein binds to chitin and heparin, activating multiple signaling pathways including MAPK and PI3K/AKT cascades. Elevated CHI3L1 expression is associated with various pathological conditions including cancer, fibrotic diseases, inflammatory disorders, and neurodegenerative conditions such as Alzheimer's disease. Its levels in serum and tissues correlate with disease severity and progression in multiple malignancies and chronic inflammatory states.
OCX-253 represents a therapeutic antibody candidate investigated for its potential to neutralize CHI3L1 activity in disease contexts. This biosimilar provides researchers with a valuable tool for investigating CHI3L1-mediated biological processes, validating therapeutic targets, and exploring the protein's role in tumor microenvironments, fibrosis development, and inflammatory responses. It enables mechanistic studies of CHI3L1 signaling pathways and supports preclinical research in oncology and inflammation-related fields.
There are currently no reviews for this product.